Cipla inks pact with Eli Lilly to produce, sell COVID-19 treatment drug


PTI, May 10, 2021, 10:59 AM IST

New Delhi: Drug major Cipla on Monday said it has inked a pact with US-based Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of COVID-19.

The Mumbai-based company said it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for baricitinib.

Baricitinib has already received a restricted emergency use approval by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This collaboration is a step further in the company”s efforts to enhance access to critical treatments for patients affected by the pandemic, Cipla said in a statement.

The company will leverage its extensive distribution footprint to make this therapy accessible to more patients and markets, it added.

“Through the pandemic, Cipla has been at the forefront of COVID care and our partnership with Lilly is a demonstration of our unwavering commitment to care towards patients impacted by COVID-19,” Cipla Ltd MD and Global CEO Umang Vohra noted.

Cipla had last year launched a generic version of antiviral drug remdesivir to treat COVID-19 patients. The drug firm had also introduced antibody detection kits for COVID-19 in the country under the brand name ”ELIFast” in partnership with KARWA Ltd, under the technology transfer from the Indian Council of Medical Research (ICMR).

Amid spiralling cases of COVID-19 in the country amid the second wave, drug firms have been collaborating to come out with drugs to treat the highly infectious disease.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Lok Sabha Elections 2024: One killed, three injured in post-poll violence in Bihar’s Saran

“What an honour”: Sushmita Sen celebrates 30 years of Miss Universe title

Maddock Films unveils ‘Munjya’, movie to release on June 7

Bengaluru cafe blast case: NIA conducts multi-state raids

Understanding bladder cancer: What we know and what we don’t

Mother of infant rescued from Chennai residential apartment dies by suicide

‘Rajiv’s life was short but ‘impactful’, liberalisation his legacy’

Related Articles More

Indian markets decline in early trade on weak trends from Asian peers, foreign fund outflows

Tata Motors’ arms partner with Bajaj Finance to provide financing to passenger, EV dealers

Rajnish Kumar, Mohandas Pai to discontinue as Byju’s advisors

Drug makers Dr Reddy’s, Sun Pharma, Aurobindo recall products in US

FPIs withdraw Rs 28,200 cr from Indian equities on poll jitters, attractive Chinese mkt valuations

MUST WATCH

Peacock rescued from well

Popular Guruprasad Restaurant

Haralukote Shri Anjaneya Swamy |Udayavani

Caring For Your Newborn baby

Sri Lanka temple


Latest Additions

Mysuru: Woman stabbed to death allegedly by her husband

Actor Mohanlal turns 64; fans, colleagues extend hearty wishes

Lok Sabha Elections 2024: One killed, three injured in post-poll violence in Bihar’s Saran

Sanjay Raut accuses election commission of bias amid voting slowdown

“What an honour”: Sushmita Sen celebrates 30 years of Miss Universe title

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.